CN114392383A - 一种可降解栓塞微球及其制备方法 - Google Patents
一种可降解栓塞微球及其制备方法 Download PDFInfo
- Publication number
- CN114392383A CN114392383A CN202210054296.XA CN202210054296A CN114392383A CN 114392383 A CN114392383 A CN 114392383A CN 202210054296 A CN202210054296 A CN 202210054296A CN 114392383 A CN114392383 A CN 114392383A
- Authority
- CN
- China
- Prior art keywords
- microsphere
- degradable
- embolism
- embolic
- mixed solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 56
- 208000005189 Embolism Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 239000002245 particle Substances 0.000 claims abstract description 14
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 11
- 239000003999 initiator Substances 0.000 claims abstract description 11
- 229920002521 macromolecule Polymers 0.000 claims abstract description 11
- 238000004132 cross linking Methods 0.000 claims abstract description 7
- 230000000379 polymerizing effect Effects 0.000 claims abstract description 4
- 230000003073 embolic effect Effects 0.000 claims description 13
- 239000011259 mixed solution Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 5
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 5
- 239000005662 Paraffin oil Substances 0.000 claims description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical group C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 5
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000013270 controlled release Methods 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 3
- 230000010102 embolization Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Surgical Instruments (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种可降解栓塞微球,为具有生物降解性的功能化大分子通过引发剂、交联剂交联聚合形成的栓塞微球。本发明还提供了一种可降解栓塞微球的制备方法。本发明提供的可降解栓塞微球,具有良好的可控缓释、生物相容性和生物降解性,能够有效改善传统的微球颗粒在人体内的蓄积,是一种良好的药物控制释放体系。
Description
技术领域
本发明涉及医用材料技术领域,尤其涉及一种可降解栓塞微球及其制备方法。
背景技术
介入治疗是在影像设备引导下的一种微创医疗技术,经导管血管栓塞术是介入治疗的重要技术,经导管血管栓塞术以其微创性、全程影像引导和选择性靶血管插入技术以及定位准确等优点,在介入放射治疗领域得到越来越广泛的应用。经导管血管栓塞术将载有抗肿瘤药的人工合成的栓塞材料经过导管注入血管,从而使血管堵塞,达到阻断血管向肿瘤部位供血,并释放抗肿瘤药物,其关键是选择合适的栓塞剂。
目前,临床所用的栓塞材料主要包括不可载药的栓塞材料,如明胶海绵颗粒、聚乙烯醇(PVA)、Embosphere,以及可载药的栓塞微球,如DC-Bead、伽俐生微球、Hepasphere微球等。这些微球多为不可降解微球,在抗肿瘤药物释放完之后,长期在血管内累积,会影响血管内血液的正常流通。
因此,本领域的技术人员致力于提供一种可降解的栓塞微球及其制备方法,以解决现有的栓塞微球不可降解的问题。
发明内容
有鉴于现有技术上的缺陷,本发明所要解决的技术问题是如何提供一种能够在人体内降解的栓塞微球及其制备方法。
为实现上述目的,本发明提供了一种可降解栓塞微球,其为具有生物降解性的功能化大分子通过引发剂、交联剂交联聚合形成的栓塞微球。
优选地,所述具有生物降解性的功能化大分子是PLGA、PCL、PLA、PHA。
优选地,所述引发剂是N,N-亚甲基双丙烯酰胺。
优选地,所述交联剂是过氧化苯甲酰。
优选地,所述可降解微球颗粒的粒径是1~5μm。
优选地,所述可降解微球颗粒的表面吸附有丙烯酸。
本发明还提供了一种可降解栓塞微球的制备方法,所述方法包括以下步骤:
将具有生物降解性的功能化大分子、引发剂、交联剂混合,得到混合溶液;
将所述混合溶液逐滴加入预装有石蜡油和span-80的容器中,加入催化剂,并旋转一定时间,形成栓塞微球;
用有机溶剂将所述栓塞微球表面洗净,并进行干燥。
优选地,所述混合溶液中还包括丙烯酸。
优选地,所述混合溶液旋转时的转速为300~600转/min。
优选地,所述有机溶剂为二氯甲烷、甲醇、乙醇、丙酮、四氢呋喃、正丁醇、异丁醇、仲丁醇或正己烷中的任意一种或至少两种的组合。
本发明至少具有如下有益技术效果:
本发明提供的可降解栓塞微球,利用聚乳酸羟基乙酸共聚物与含氨基物质的交联形成微球颗粒,具有良好的可控缓释、生物相容性和生物降解性,能够有效改善传统的微球颗粒在人体内的蓄积,是一种良好的药物控制释放体系。
以下将结合附图对本发明的构思、具体结构及产生的技术效果作进一步说明,以充分地了解本发明的目的、特征和效果。
附图说明
图1是本发明的可降解栓塞微球的制备方法示意图。
具体实施方式
以下介绍本发明的优选实施例,使其技术内容更加清楚和便于理解。本发明可以通过许多不同形式的实施例来得以体现,本发明的保护范围并非仅限于文中提到的实施例。
在附图中,结构相同的部件以相同数字标号表示,各处结构或功能相似的组件以相似数字标号表示。附图所示的每一组件的尺寸和厚度是任意示出的,本发明并没有限定每个组件的尺寸和厚度。为了使图示更清晰,附图中有些地方适当夸大了部件的厚度。
本发明提供了一种可降解栓塞微球,通过具有生物降解性的功能化大分子通过引发剂、交联剂聚合形成。
为实现栓塞微球的可降解性,本实施例的具有生物降解性的功能化大分子为聚乳酸羟基乙酸共聚物(PLGA),PLGA是由乳酸和乙醇酸按一定比例聚合而成额高分子共聚物,含有较多的末端羟基和羧基,可用于含氨基物质的交联,是一种良好的药物载体。PLGA在20~42℃的温度范围内具有良好的生物降解性,对人体无毒副作用。另外,PLGA微球控释系统具有良好的生物学特性,长期使用体内无蓄积,并且能够延缓药物释放时间,是一种良好的药物控制释放体系。
本实施例的引发剂是N,N-亚甲基双丙烯酰胺,交联剂是过氧化苯甲酰,通过PLGA末端的羟基和羧基,实现对氨基物质的交联,形成一种能载药的栓塞微球颗粒。
为了实现对药物颗粒的吸附,在PLGA、N,N-亚甲基双丙烯酰胺、过氧化苯甲酰交联形成的微球颗粒表面可以涂以丙烯酸,使微球颗粒的表面带有静电,实现对药物颗粒的吸附。本实施例制成的栓塞微球的直径为1~5μm。
本发明还提供了一种可降解栓塞微球的制备方法,如图1所示,本发明的制备方法包括以下步骤:
将具有生物降解性的功能化大分子、引发剂、交联剂混合,得到混合溶液;
将混合溶液逐滴加入预装有石蜡油和span-80的容器中,加入催化剂,并旋转一定时间,形成栓塞微球;
用有机溶剂将所述栓塞微球表面洗净,并进行干燥。
为了使栓塞微球的表面带电,在功能化大分子、引发剂、交联剂的混合溶液中还可以加入丙烯酸。
有机溶剂可以为二氯甲烷、甲醇、乙醇、丙酮、四氢呋喃、正丁醇、异丁醇、仲丁醇或正己烷中的任意一种或至少两种的组合,通过有机溶剂将栓塞微球表面的石蜡清洗干净。
本发明公开了一种可降解栓塞微球的具体制备方法:取10ml质量分数为5%的PLGA溶液,1ml体积分数为5%的丙烯酸、质量为1g的N,N-亚甲基双丙烯酰胺、以及质量为1g的过氧化苯甲酰,制成混合溶液;在反应容器中加入100ml的石蜡油和10g的span-80,混合;将混合溶液逐滴进入装有石蜡油和span-80的反应容器中,加入催化剂,以300转/min的转速旋转20min,得到栓塞微球;最后,用二氯甲烷溶剂对栓塞微球进行清晰,将表面的石蜡清洗干净,得到干燥的栓塞微球。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术无需创造性劳动就可以根据本发明的构思作出诸多修改和变化。因此,凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到。
Claims (10)
1.一种可降解栓塞微球,其特征在于,其为具有生物降解性的功能化大分子通过引发剂、交联剂交联聚合形成的栓塞微球。
2.如权利要求1所述的可降解栓塞微球,其特征在于,所述具有生物降解性的功能化大分子是PLGA、PCL、PLA、PHA。
3.如权利要求1所述的可降解栓塞微球,其特征在于,所述引发剂是N,N-亚甲基双丙烯酰胺。
4.如权利要求1述的可降解栓塞微球,其特征在于,所述交联剂是过氧化苯甲酰。
5.如权利要求1所述的可降解栓塞微球,其特征在于,所述可降解微球颗粒的粒径是1~5μm。
6.如权利要求1所述的可降解栓塞微球,其特征在于,所述可降解微球颗粒的表面吸附有丙烯酸。
7.如权利要求1-6任一项所述的可降解栓塞微球的制备方法,其特征在于,所述方法包括以下步骤:
将具有生物降解性的功能化大分子、引发剂、交联剂混合,得到混合溶液;
将所述混合溶液逐滴加入预装有石蜡油和span-80的容器中,加入催化剂,并旋转一定时间,形成栓塞微球;
用有机溶剂将所述栓塞微球表面洗净,并进行干燥。
8.如权利要求7所述的可降解栓塞微球的制备方法,其特征在于,所述混合溶液中还包括丙烯酸。
9.如权利要求7所述的可降解栓塞微球的制备方法,其特征在于,所述混合溶液旋转时的转速为300~600转/min。
10.如权利要求7所述的可降解栓塞微球的制备方法,其特征在于,所述有机溶剂为二氯甲烷、甲醇、乙醇、丙酮、四氢呋喃、正丁醇、异丁醇、仲丁醇或正己烷中的任意一种或至少两种的组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210054296.XA CN114392383A (zh) | 2022-01-18 | 2022-01-18 | 一种可降解栓塞微球及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210054296.XA CN114392383A (zh) | 2022-01-18 | 2022-01-18 | 一种可降解栓塞微球及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114392383A true CN114392383A (zh) | 2022-04-26 |
Family
ID=81231556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210054296.XA Pending CN114392383A (zh) | 2022-01-18 | 2022-01-18 | 一种可降解栓塞微球及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114392383A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103990185A (zh) * | 2014-05-19 | 2014-08-20 | 东南大学 | 一种卡拉胶和明胶微球栓塞剂及其制备方法 |
CN108686259A (zh) * | 2018-07-12 | 2018-10-23 | 中国人民解放军总医院 | 用于血管内栓塞x线下可显影的载药微球及其制备方法 |
US20200368171A1 (en) * | 2019-05-23 | 2020-11-26 | Microvention, Inc. | Particles |
CN113694248A (zh) * | 2021-09-13 | 2021-11-26 | 中山大学 | 一种基于可溶性淀粉的栓塞微球及其制备和应用 |
-
2022
- 2022-01-18 CN CN202210054296.XA patent/CN114392383A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103990185A (zh) * | 2014-05-19 | 2014-08-20 | 东南大学 | 一种卡拉胶和明胶微球栓塞剂及其制备方法 |
CN108686259A (zh) * | 2018-07-12 | 2018-10-23 | 中国人民解放军总医院 | 用于血管内栓塞x线下可显影的载药微球及其制备方法 |
US20200368171A1 (en) * | 2019-05-23 | 2020-11-26 | Microvention, Inc. | Particles |
CN113694248A (zh) * | 2021-09-13 | 2021-11-26 | 中山大学 | 一种基于可溶性淀粉的栓塞微球及其制备和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
El‐Sherif et al. | Development of a novel method for synthesis of a polymeric ultrasound contrast agent | |
CA2584122C (en) | Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same | |
RU2662818C2 (ru) | Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений | |
KR101125232B1 (ko) | 초상자성 산화철 나노입자 탑재 고분자 미세구의 제조 방법 | |
CN109265942B (zh) | 一种聚乳酸微球及其制备方法与应用 | |
Vaibhav et al. | Microspheres: a promising drug carrier | |
JP2011115601A (ja) | 粒子固定化コーティングおよびその使用 | |
Ulubayram et al. | Gelatin microspheres and sponges for delivery of macromolecules | |
El‐Sherif et al. | Ultrasound degradation of novel polymer contrast agents | |
US20230172859A1 (en) | Drug-loaded microbead compositions, embolization compositions and associated methods | |
CN114377190A (zh) | 一种可显影的栓塞微球及其制备方法 | |
CN114392383A (zh) | 一种可降解栓塞微球及其制备方法 | |
Khan et al. | smart and active hydrogels in biotechnology—synthetic techniques and applications | |
Freundlich et al. | Bioadhesive microneedle patches for tissue sealing | |
CN114377191A (zh) | 一种可降解栓塞微球及其制备方法 | |
CN102727946B (zh) | 一种载药涂层及其制备方法 | |
Lavhate et al. | A review on microsphere | |
CN114522256B (zh) | 一种聚羟基脂肪酸酯载药放疗微球及其制备方法和应用 | |
US20090110738A1 (en) | Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same | |
CN117357686A (zh) | 可载药高分子栓塞微球及其制备方法 | |
WO2009054853A9 (en) | Loadable polymeric particles for cosmetic and reconstructive tissue augmentation applications and methods of preparing and using the same | |
CN114762675B (zh) | 一种控释型狂犬疫苗可溶性微针 | |
CN114748674A (zh) | 一种预载药物的栓塞微球及加工方法 | |
WO2024134220A1 (en) | Cavitation-inducing biodegradable polymeric particles | |
CN101401959B (zh) | 明胶-壳聚糖-β-磷酸三钙球形多孔颗粒材料的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |